The spinal muscular atrophy (SMA) protein, survival motor neuron (SMN), functions in the biogenesis of small nuclear ribonucleoproteins (snRNPs). SMN has also been implicated in tissue-specific functions; however, it remains unclear which of these is important for the etiology of SMA. Smn null mutants display larval lethality and show significant locomotion defects as well as reductions in minor-class spliceosomal snRNAs. Despite these reductions, we found no appreciable defects in the splicing of mRNAs containing minor-class introns. Transgenic expression of low levels of either wild-type or an SMA patient-derived form of SMN rescued the larval lethality and locomotor defects; however, snRNA levels were not restored. Thus, the snRNP biogenesis function of SMN is not a major contributor to the phenotype of Smn null mutants. These findings have major implications for SMA etiology because they show that SMN's role in snRNP biogenesis can be uncoupled from the organismal viability and locomotor defects.
INTRODUCTION
Spinal muscular atrophy (SMA) is caused by recessive loss-offunction mutations in the survival motor neuron 1 (SMN1) gene (Lefebvre et al., 1995) . The disease is characterized by motor neuron loss, atrophy of the proximal muscles, and progressive symmetrical paralysis. SMA symptoms vary in severity and are classified by types I to IV, ranked in decreasing order (Ogino and Wilson, 2004) . In the most severe form (SMA type I), which is also the most common, death usually occurs by two years of age.
SMN is the central component of a multimeric protein assemblage known as the SMN complex ). The best-characterized function of this complex is in the biogenesis of small nuclear ribonucleoproteins (snRNPs), primary components of the spliceosome. The SMN complex chaperones assembly of Sm proteins onto spliceosomal snRNAs (Meister et al., 2001; Pellizzoni et al., 2002) . Complete loss of SMN is lethal in all organisms investigated to date. SMA, therefore, is a disease that arises because of a reduction in SMN levels, not a complete loss. Humans have two paralogs of SMN, named SMN1 and SMN2, both of which contribute to total cellular levels of SMN protein. SMN2, however, contains a base change that primarily leads to production of a truncated, unstable protein product. Current estimates suggest that SMN2 produces only 10%-15% of the level of full-length protein produced by SMN1 (Lorson et al., 2010) . Although this amount is not enough to completely compensate for loss of SMN1, SMN2 is sufficient to rescue embryonic lethality.
A causative link between SMN1 and SMA was established over 15 years ago; however, the mechanism of disease pathology remains unclear. In addition to roles in snRNP biogenesis, SMN has been implicated in a number of tissue-specific processes, including axonal pathfinding (McWhorter et al., 2003; Sharma et al., 2005) , axonal transport of b-actin mRNP (Rossoll et al., 2003) , neuromuscular junction formation and function (Chan et al., 2003; Kariya et al., 2008; Murray et al., 2008; Kong et al., 2009) , myoblast fusion (Shafey et al., 2005) , and maintenance of muscle architecture (Rajendra et al., 2007; Walker et al., 2008; Bowerman et al., 2009) . Thus, it is not surprising that therapeutic approaches targeting SMA are primarily focused on increasing production of full-length SMN protein from the SMN2 gene in patients (Lorson et al., 2010) . Although these approaches are extremely important, it is clear that a deeper understanding of the molecular etiology of SMA will be essential to develop effective treatments and minimize side effects.
Here, we present a Drosophila model system to study SMA patient-derived loss-of-function mutations in the background of an Smn null allele. Smn null mutants display a reduction in the levels of a subset of snRNAs and considerable defects in larval locomotion. Transgenic expression of FLAG-tagged wildtype (WT) dSMN rescues larval locomotion and organismal viability but, surprisingly, fails to rescue snRNA levels. Expression of an Smn T205I construct (which mimics SMN T274I in humans) also rescues the larval motility and viability defects, but the majority of these animals die as pupae with an snRNA profile similar to that of the wild-type transgenics. These data show that the observed decreases in snRNA levels in Smn null animals are not major contributors to organismal phenotype and indicate that non-snRNP biogenesis functions of SMN play important roles in SMA pathology.
RESULTS AND DISCUSSION

Characterization of Smn Null Flies
In order to minimize genetic background effects arising from recessive second-site mutations, we used flies bearing two different Smn null alleles for phenotypic characterization. Smn D/+ flies (Rajendra et al., 2007) were crossed with Smn X7/+ (Chang et al., 2008) . Smn À/À larvae begin to die in early third instar, $80 hr (day 4) post-egg-laying ( Figure 1A ). The primary lethal phase continues through day 5, after which time the number of larvae reduces gradually. Consistent with previous observations (Shpargel et al., 2009 ), 20%-30% of Smn null larvae are ''long lived'' and can survive for many days without undergoing metamorphosis or exhibiting the wandering behavior typical of the late third instar. Larval dSMN levels are highest at 1 day post-egg-laying (DPE) and then decrease and remain constant. In Smn À/À mutants, dSMN levels are already reduced on day 1 and are almost undetectable by 2 DPE (Figure 1B) . Thus, a significant fraction of animals are able to survive for long periods with very low levels of dSMN.
To determine whether a correlation exists between dSMN and snRNA levels, developmentally staged Smn À/À and Oregon-R (OR) larvae were harvested and split into two groups of $20-50 animals. One group was used to extract protein for western analysis and the other for RNA extraction and northern blotting ( Figure 1C ). The snRNA levels in both OR and Smn null flies were greatest on day 1, after which time they decreased and remained constant throughout larval development. This was a surprising finding in the mutant larvae because dSMN levels are severely reduced by 2 DPE, yet no dramatic or progressive reduction in snRNA levels was observed. We did note a slight decrease in U1, U5, and U11 snRNAs in the mutants and a greater decrease in levels of U12 and U4atac snRNAs (Figure 1C) . These findings are consistent with observations in the mammalian system that minor-class snRNAs (particularly U4atac and U12) are more sensitive to SMN depletion (Gabanella et al., 2007; Workman et al., 2009) . We also note that levels of U6atac appear to be upregulated in the Smn À/À larvae, although the molecular basis for this is currently unknown. We did not detect an increase in unassembled snRNAs in mutant larvae, as shown by coimmunoprecipitation with anti-Sm antibody, Y12 ( Figure S1 ). Thus, as observed in mammalian cell culture systems (Sauterer et al., 1988) , total Drosophila snRNA levels reflect total snRNP levels. The observed decrease in U4atac and U12 snRNAs in Smn null larvae was neither exacerbated by prolonged reduction of dSMN nor did it result in appreciable defects in the splicing of minor-class (U12-type) introns. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis was performed using RNA from Smn À/À and wild-type larvae.
Relative levels of spliced mRNAs from genes that contain U12-type introns were measured (Figure 2 ). Hypomorphic U6atac larvae (U6atac
), which are known to be defective in U12-dependent splicing (Otake et al., 2002; Pessa et al., 2010) , were used as positive controls. As shown in Figure 2 , mRNAs from these genes were significantly reduced in U6atac mutants, whereas they were largely unaffected in Smn mutants. of larvae surviving for extended periods without pupariation. Note that by 6 DPE the OR control larvae had all pupated. For each genotype n R 100 larvae, collected on day 1 post-egg-laying. (B) Developmental western blot of dSMN levels in control (OR) and Smn null animals.
(C) Developmental northern blot showing major and minor class spliceosomal snRNA levels in OR and Smn null larvae. 7SK and U6 snRNA are shown as loading controls. These snRNA levels are reflective of the total snRNP levels, as shown in Figure S1 . An asterisk marks a heteroallelic variant U11 snRNA present in the Smn null background (see Figure S1 ).
Transgenic Expression of an SMA Patient-Derived Mutation in dSMN Rescues
Although analysis of Smn null mutants is informative, the many putative functions of SMN make it difficult to parse out the precise cause of lethality. We thus wanted to develop Drosophila SMA models that perturb only a subset of SMN functions rather than affecting all of them. As a proof of principle, we created flies expressing an SMA patient-derived point mutation, T205I. This mutation corresponds to an SMA type II/III mutation, T274I, located in the YG box domain of SMN (Sun et al., 2005) . We generated transgenic flies carrying either a wild-type or T205I mutant transgene, inserted at site 86Fb on chromosome 3 (Bischof et al., 2007) . To preserve endogenous expression patterns, constructs are driven by the native Smn promoter and contain native 3 0 and 5 0 flanking sequences. Transgenic proteins can be distinguished from the endogenous by the presence of an N-terminal 3X FLAG tag.
Expression of the wild-type construct (Smn WT ) in the Smn
background results in >70% rescue of lethality ( Figure 3A ). The surviving adults are fertile, with no apparent defects in flight or motility. Similarly, expression of the Smn T205I construct fully rescues larval lethality of the null mutant. And, whereas $25% of Smn T205I mutants eclose as adults, the majority of these animals die as pupae ( Figure 3A ). This partial rescue of the null phenotype is consistent with the human SMN T274I mutation, which causes a relatively mild form of SMA (Sun et al., 2005) . Note that both the WT and T205I rescue animals show some developmental delay because they pupate and eclose a day later than OR controls.
Smn T205I Is Moderately Defective in Self-Oligmerization
A number of human SMA-derived mutations in the YG box region of SMN, including SMN T274I , have been shown to be defective in oligomerization (Lorson et al., 1998) . We tested a panel of dSMN proteins, including T205I, for similar defects. FLAG-and Myctagged versions of each construct were expressed in Drosophila S2 cells and coimmunoprecipitation profiles compared. Immunoprecipitation was performed with anti-FLAG antibody, and the amount of Myc-tagged protein that coprecipitated was measured. As shown in Figure 3B , the amount of MycdSMN(T205I) precipitated by FLAG-dSMN(T205I) was reduced compared to the amount of Myc-dSMN(WT) precipitated by FLAG-dSMN(WT), indicating a deficiency in its ability to selfoligomerize. This conservation between the human and fly SMN mutants also extends to other SMA-derived point mutations. Both Smn G206S (corresponding to human SMN G275S ) and , and U6atac À/À larvae were measured by qRT-PCR and normalized to OR using Rpl32 mRNA. Samples were run in technical triplicates for each of three biological replicates. The error bars indicate standard error of the mean. Primers were designed to cross the exon junction flanking the U12-type intron such that only spliced mRNAs would be detected (inset). The U6atac À/À larvae showed robust defects in splicing of these introns (avg. = 0.32). Nine of the 18 mRNAs were reduced in U6atac À/À animals with p values < 0.01, eight had p < 0.05, and the levels of one mRNA approached, but did not reach, significance (CG7892, p $0.08). In contrast, splicing of these same introns was relatively unaffected in Smn À/À animals (avg. = 1.06). Although a majority of the mRNAs were not affected, we note that the four mRNAs showing the greatest decrease in the Smn À/À mutants were also the most severely affected mRNAs in U6atac À/À mutants. Each of these (CG18177, CG33108, CG15081, and CG11839) had p values < 0.05, although none were below 0.01.
Smn Y203C (SMN Y272C ) mutants were defective in oligomerization, similar to reports of their human counterparts (Lorson et al., 1998) . Furthermore, the severity of these defects is also conserved, as Y203C was less effective at binding to itself than either T205I or G206S ( Figure 3D ). Likewise, Y272C has a more severe oligomerization defect than T274I (Lorson et al., 1998) . Thus, T205I displays a relatively mild defect in selfoligomerization.
SMN molecules that are unable to oligomerize are unstable ). Thus, we expected that T205I transgenic flies might display reduced levels of FLAG-dSMN compared to transgenic flies expressing WT FLAG-dSMN. However, levels of FLAG-dSMN in both the WT and T205I transgenic lines were equivalent, as analyzed by western blotting ( Figure 3C ). This finding indicates that the mild defect in T205I oligomerization does not significantly affect dSMN levels. In addition, this suggests that the lethality of the T205I mutant is not due to insufficient protein levels but rather due to a molecular defect in dSMN.
As shown in Figure 3C , expression of both transgenic FLAGdSMN constructs (WT and T205I) was significantly below the level of endogenous dSMN. The considerable degree of rescue achieved with such low expression levels shows that dSMN is made in greater quantities than required by the fly. Similar observations have been made in mammalian cell lines, wherein the phenotypic effects of SMN reduction are observed only when SMN levels are reduced by 85%-95% (Zhang et al., 2008; Bowerman et al., 2012) . Interestingly, we found that expression of the WT transgene with an Actin5C promoter failed to rescue the null mutant beyond pupal stages, despite the fact that this construct expressed much higher levels of dSMN protein than the native promoter driven construct ( Figure 3D ). These results suggest that the Actin5C promoter fails to express dSMN in some critical tissue or developmental window.
Transgenic Expression of Smn T205I Rescues Larval Locomotion Consistent with previous reports (Chan et al., 2003; Shpargel et al., 2009) , we found that Smn À/À animals display significant defects in larval locomotion. To further characterize these locomotor defects, we employed two previously described assays (Wu et al., 2003; Ubhi et al., 2007) . In the ''righting'' assay, each larva was placed on its dorsal surface, and the time taken to return to its ventral surface (the crawling position) was measured ( Figure 3E ). The Smn À/À larvae took a significantly longer time to return to the crawling position compared to OR. Larval motility was rescued in animals carrying the WT transgene, and to a large extent in the T205I transgenic animals, which showed a relatively mild defect. In the ''burrowing'' assay, $30 larvae were placed atop a dish containing 1.5% agar/ molasses media and incubated at room temperature in the dark. After 2 hr, the number of larvae remaining on top of the medium was recorded. The assay was repeated three times per genotype. We found that the Smn À/À mutants do not burrow into the medium at all ( Figure 3F ). However, we also noticed that if there were surface defects (cuts) present in the media, some of these larvae worked themselves into the crevices. Importantly, the burrowing behavior was restored in both the WT and T205I transgenic animals ( Figure 3F ). We conclude that Smn T205I rescues the larval viability and locomotor defects observed in the null mutants. animals. Larvae from each of the three aforementioned genotypes, along with OR, were harvested just prior to the beginning of the lethal phase (i.e., at $76 hr) and snRNA levels were analyzed by northern blotting ( Figure 4A ). As noted earlier, U1, U4, U5, U11, U12, and U4atac snRNAs showed a reduction in the null animals ( Figure 4B ). Again, U12 and U4atac levels were the most severely affected ($60% reduction). The Smn
Smn
WT
and Smn T205I animals showed very similar snRNA profiles, despite differences in adult viability. Both transgenes failed to rescue U1, U4, and U4atac snRNA levels and only partially rescued U12 and U5 snRNAs ( Figure 4B ). Thus, we conclude that the Smn T205I mutant is functional in snRNP biogenesis. In support of this interpretation, the human counterpart to this mutation, SMN T274I , was shown to be active in a HeLa cell Sm-core snRNP assembly assay (Shpargel and Matera, 2005) . We also analyzed minor-class intron splicing in the two transgenic rescue lines. Among the four mRNAs that showed slight, but significant, reductions in the Smn null mutant background (Figure 2) Figure S2 for additional information.
and Smn T205I samples ( Figure S2 ). Two of the mRNAs (CG18177 and CG15081) showed no significant differences upon expression of either transgene. CG11839 mRNA was restored to OR levels only by expression of Smn WT , whereas CG33108 levels were restored only by expression of Smn T205I ( Figure S2 ).
Smn
T205I Is a Good Model for Intermediate SMA
The human SMN T274I mutation was identified in patients with milder forms of SMA, types II/III (Sun et al., 2005) . These patients show a later age of onset, decreased severity of symptoms, and longer life expectancy than do type I patients (Ogino and Wilson, 2004) . The Drosophila equivalent of this mutation, Smn T205I , recapitulates several key features of intermediate SMA, including a slight deficiency in motor function and a much longer lifespan than the null mutant. We also observed a mild defect in oligomerization of dSMN(T205I), suggesting that on a molecular level, this Drosophila protein behaves similarly to the human mutation. We conclude that the Smn T205I flies represent a good model for intermediate SMA.
SMN, snRNA Levels, and SMA As shown above, transgenic expression of Smn WT was able to rescue the locomotion and viability defects observed in Smn null mutants; however, a majority of the snRNAs were largely unrestored to wild-type levels. Given the considerable degree of phenotypic rescue, this was an unexpected finding, suggesting that the observed reduction in snRNAs in the null animals is not a major contributor to larval locomotion and viability. Consistent with our findings, previous studies using mouse models of SMA have also reported decreases in snRNA levels, particularly for U12 and U4atac (Gabanella et al., 2007; Workman et al., 2009 ). Other investigators reported widespread pre-mRNA splicing changes in both minor-and major-class introns in latesymptomatic SMA mice (Zhang et al., 2008) . However, subsequent studies revealed that these splicing defects are likely a secondary consequence of severe SMN loss, as pre-and early-symptomatic SMA mice did not show an enrichment of unspliced introns (Bä umer et al., 2009) .
In our Drosophila system, we note that U12 and (to a lesser extent) U5 levels were partially rescued by transgenic expression of Smn WT and Smn T205I , although U4atac levels remained low ( Figure 4B ). Thus, one explanation for our results could be that splicing of minor-class (U12-specific) introns is sensitive to small changes in snRNA concentrations and that U12 and U5 are limiting factors, whereas U4atac is not. We tested this hypothesis by using qRT-PCR to measure mRNA levels in 18 of the 20 predicted minor-class introns in the Drosophila transcriptome (Lin et al., 2010) . As shown in Figure 2 , a hypomorphic mutation in the U6atac gene resulted in pronounced defects in splicing of minor-class introns; however, splicing of these same mRNAs was largely unaffected in Smn null mutants. Among the minor-intron transcripts we analyzed, the steadystate levels of two mRNAs, CG15081 (Phb2/Rea in mice) and CG33108 (ortholog unknown), were reduced by roughly 50% in Smn À/À larvae. It is possible that reduction in levels of one or more of these mRNAs could contribute to the phenotype of Smn null mutants; however, CG15081 heterozygotes are completely viable (see Flybase). A similar decrease in levels of the Phb2 mRNA in mice was shown to affect neither organismal viability nor motor function (Park et al., 2005) , strongly suggesting that haploinsufficiency for CG15081 is not the cause of the Smn phenotype. These observations question the significance of snRNA levels in human SMA etiology. In this regard, it is important to note that recessive point mutations in the gene encoding human U4atac snRNA do not phenocopy SMA. Instead, loss of U4atac function causes a disease known as microcephalic osteodysplastic primordial dwarfism type I (MOPD I), which is characterized by severe intrauterine growth retardation and multiple organ abnormalities (Edery et al., 2011; He et al., 2011) . Similar to the fruitfly U6atac mutants (Pessa et al., 2010 ; this work), cells derived from MOPD I patients display marked defects in splicing of minorclass introns, whereas splicing of major-class (U2-type) introns is unaffected (Edery et al., 2011; He et al., 2011) . Although we cannot entirely exclude the possibility that tissue-specific defects in minor-intron splicing may be causative for SMA, our finding that transgenic expression of Smn WT can rescue viability and fertility without restoring U4atac levels effectively uncouples the observed global snRNA deficits from the organismal phenotype. Moreover, it is important to note that the Smn and U6atac mutants were analyzed just prior to onset of the lethal phase. At this time point, Smn null animals already display significant motor function defects. We therefore conclude that perturbations in minor spliceosome levels are not likely to be causative for the larval locomotion and viability defects observed in Smn null mutants.
With the possible exception of U5, Smn T205I animals have nearly identical snRNA profiles to those of the Smn WT animals, yet most of the T205I animals die as pupae. Given the intermediate phenotype of both humans and fruit flies expressing the T274I/T205I mutation and the fact that human SMN T274I is active in Sm-core assembly (Shpargel and Matera, 2005) , these findings strongly suggest that mutation of this residue disrupts a second, essential function of SMN protein. This does not mean that splicing plays no role in downstream SMA pathology; it clearly does. There is strong evidence for a negative feedback loop wherein low levels of SMN protein exacerbate exon skipping of human SMN2, leading to a further reduction in SMN expression (Jodelka et al., 2010; Ruggiu et al., 2012) . However, because Smn is a single-exon gene in Drosophila, our system also uncouples protein-based defects in SMN from autologous feedback regulation via splicing. In conclusion, our results demonstrate that the reduction in snRNA levels observed in Smn mutants is not a major contributor to organismal lethality and indicate that non-snRNP biogenesis functions of SMN play critical roles in the etiology of SMA. Molecular identification of this second SMN function will be an important subject of future investigation.
EXPERIMENTAL PROCEDURES Fly Stocks and Genetics
All stocks were cultured on molasses and agar at room temperature (24 ± 1 C)
in half-pint bottles. Oregon-R was used as the wild-type allele. (Rajendra et al., 2007) . WT and T205I transgene constructs were made using a $3kb fragment encompassing the entire Smn coding region, cloned into the pAttB vector (Bischof et al., 2007 
Antibodies and Western Blotting
Larval, pupal, and adult lysates were prepared by crushing the animals in lysis buffer (50mM Tris-HCl [pH 7.5], 150 mM NaCl, 1mM EDTA, 1% NP-40) with 1X protease inhibitor cocktail (Invitrogen, Carlsbad, CA, USA) and clearing the lysate by centrifugation. Western analysis was performed using standard protocols. Rabbit anti-dSMN serum was generated by injecting rabbits with purified full-length dSMN protein (Pacific Immunology Corp., Ramona, CA, USA) and was subsequently affinity purified. For western blotting, dilutions of 1 in 2,500 for the affinity purified anti-dSMN, 1 in 10,000 for anti-a tubulin (Sigma-Aldrich, St. Louis, MO, USA), and 1 in 10,000 for polyclonal anti-Myc (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used. Anti-FLAG antibody crosslinked to agarose beads (EZview Red Anti-FLAG M2 affinity gel, Sigma-Aldrich) was used to immunoprecipitate FLAGtagged proteins.
Northern Blotting
Larvae, pupae, and adult Drosophila were homogenized in TRIZOL (Invitrogen) and total RNA was extracted following the manufacturer's instructions. RNA was run on a 10% polyacrylamide-urea gel (Invitrogen), transferred to a nylon membrane, and probed with 32 P-labeled PCR products corresponding to the Drosophila melanogaster U1, U2, U4, U5, U6, U11, U12, U4atac, U6atac, and 7SK cDNAs. The blots were visualized using a Typhoon phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA), and quantification was performed by densitometry using ImageQuant software.
Larval Motility Assays
Larvae used for the motility assays were $76 hr old. For the righting assay, larvae were placed on a 3% agarose plate for 120 s to allow them to equilibrate to the new environment. They were then placed on their dorsal surfaces, and the time taken to return to a crawling position was noted. The assay was terminated at 120 s. For the burrowing assay, 30 larvae were placed on a molasses plate with 1.5% agarose. The plates were kept in the dark, and the number of larvae remaining on the surface was counted after 2 hr. Statistical significance for righting and burrowing assays was determined using Student's t test and chi-square analysis, respectively.
Real-Time PCR
One microgram of total RNA from $76 hr larvae was used in a 20 ml reverse transcriptase reaction with random hexamer primers (Superscript III first strand synthesis system, Invitrogen), and $50-100 ng of the cDNA was used for qRT-PCR. Real-time PCR reactions were carried out on an Applied Biosystems 7900HT Fast Real-time PCR machine using Maxima SYBR Green/Rox qPCR master mix (Fermentas, Burlington, Ontario, Canada). Three technical replicates were run for each reaction, and three biological replicates were tested for each genotype. A 2-step PCR reaction was used, and the data were analyzed using the DDCt method. 
SUPPLEMENTAL INFORMATION
Supplemental Information EXTENDED RESULTS
Variant Forms of snRNAs
In addition to the canonical forms, we also observed expression of U5 and U11 snRNA variants (see Figure S1 ). Consistent with a previous report, the variant forms of U5 are predominantly expressed early in larval development (Chen et al., 2005) . The Smn À/À larvae express a variant form of U11, that contains a 22 bp deletion in stem loop II, a region that is not well conserved among Drosophilid species ( Figure S1 ). The U11 and Smn genes are both on the same chromosome, and we note that this U11 variant tracks with the Smn D allele and is not present on the homolog containing Smn X7 . We also note that the variant U11 snRNA can be immunoprecipitated by anti-Sm antibodies ( Figure S1 ) and that Smn D homozygotes can be rescued by transgenic expression of dSMN (Rajendra et al., 2007, this work) . Thus, this variant U11 allele appears to be fully functional.
EXTENDED EXPERIMENTAL PROCEDURES Immunoprecipitation
Larvae were homogenized in NET (150 mM NaCl, 5 mM EDTA, 50 mM Tris pH 7.5, 0.5% NP40) buffer, clarified by spinning at 10,000xg for 10 min at 4 C. Immunoprecipitation was performed by incubating lysates with monoclonal Y12 antibody bound beads for 2 hr, washing the beads in NET buffer and then placing them in TRIZOL for RNA extraction. Y12. The bound snRNAs were visualized via Northern blotting with probes specific to the indicated snRNAs and 5.8S rRNA, which binds non-specifically to beads and used as an approximate load control. The levels of snRNAs co-precipitated for OR and Smn X7/D were similar to the total level of snRNAs in the input.
(B) An illustration of the secondary structures of the canonical and variant forms of U11. The structures are based on those of Schneider et al. (2004) and redrawn using VARNA (Darty et al., 2009 
